Guardian Pharmacy Services, Inc. (GRDN) company profile
Close on Nov 12, 2026Market cap $3.13BP/E –Yield –
About Guardian Pharmacy Services
Retail-Drug Stores and Proprietary Stores, SIC 5912
Guardian Pharmacy Services, Inc. provides comprehensive, technology-enabled pharmacy services tailored primarily for residents of long-term care facilities. The company specializes in individualized clinical care, automated robotic drug dispensing, compliance packaging, and medication administration support. Its operations focus primarily on serving assisted living facilities, behavioral health communities, and group homes, while also supporting residents in skilled nursing facilities. In addition to dispensing pharmaceuticals, the company coordinates prescription benefit plan coverage, integrates with electronic medication administration records, and delivers caregiver training, consulting services, and regulatory compliance audits.
As of December 31, 2025, the company operates 61 pharmacies—including 54 full-service locations—that serve approximately 205,000 residents across roughly 8,400 long-term care facilities in 38 states. Guardian Pharmacy Services maintains its principal executive offices in Atlanta, Georgia.
Summary of the business section of Guardian Pharmacy Services's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Guardian Pharmacy Services, Inc.
- Headquarters
- Atlanta, GA
- Address
- 300 Galleria Parkway Se, Suite 800 30339
- Phone
- (404) 810-0089
- Website
- guardianpharmacy.com
- Employees
- 3,600, Dec 31, 2025
- Industry
- Retail-Drug Stores and Proprietary Stores
- Incorporated in
- Georgia
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Atlanta, Georgia
Stock & identifiers
- Ticker
- GRDN
- Exchange
- NYSE
- IPO date
- Sep 26, 2024
- Shares outstanding
- 63M, Aug 3, 2026
- Public float
- $411.60M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1802255
- CUSIP
- 40145W101
- ISIN
- US40145W1018
- FIGI
- BBG01JM69P40
- Share class FIGI
- BBG01JM69PZ6
- EIN
- 20-0100834
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David K. Morris | See Remarks, Director | 896,341 |
| Fred Burke | See Remarks, Director | 3,438,064 |
| Douglas Towns | See Remarks | 113,006 |
| Richard Eakins | Senior Vice President, Sales | 134,930 |
| Jeffrey Tuch | See Remarks | 231,847 |
| Robert Weir | See Remarks | 103,333 |
| David Norman Martin | See Remarks | 140,905 |
| Chris Crisafulli | See Remarks | 53,057 |
| William Franklin Mudd | See Remarks | 136,747 |
| Thomas J. Salentine Jr | Director | 16,705,380 |
| John Ackerman | Director | 5,151,043 |
| William E. Bindley | Director | 16,669,666 |
| Mary Sue Patchett | Director | 15,071 |
| Steven D. Cosler | Director | 29,012 |
| Randall J. Lewis | Director | 15,071 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $845.84K | $845.84K | $995.72K | $188 | – |
| FY2024 | $766.10K | $766.10K | $682.68K | $127 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Fred Burke President and Chief Executive Officer | $463.50K | – | $347.63K | $34.72K | $845.84K | +10% |
| David Morris Executive Vice President and Chief Financial Officer | $412.00K | $240.00K | $309.00K | $35.71K | $996.70K | +46% |
| Kendall Forbes Executive Vice President, Sales & Operations | $412.00K | $240.00K | $309.00K | $33.74K | $994.73K | +46% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 26, 2024
- Offer price
- $14.00
- Securities offered
- 8,000,000
- Gross proceeds
- $112.00M
- Exchange
- NYSE
- First trading day
- Sep 26, 2024
- First-day close
- $16.00+14.3%
- Lock-up ends (est.)
- Mar 25, 2025
“The public offering price is $14.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed approximately 3,600 persons, all of whom are located within the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 26, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 25, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jul 23, 2021 | Name change | Name changed from Guardian Pharmacy, LLC to Guardian Pharmacy Services, Inc. |
See a number that looks wrong?